替罗非班治疗不同部位进展性脑梗死的临床研究  

Clinical Study of Tirofiban in the Treatment of Different Sites of Progressive Ischemic Stroke

作　　者：章子骏 付杰 韩静霆 ZHANG Zijun;FU Jie;HAN Jingting(Department of Neurology,Shangrao People's Hospital,Shangrao 334000,China;不详)

机构地区：[1]上饶市人民医院神经内科,江西上饶334000

出　　处：《中国医学创新》2024年第23期57-60,共4页Medical Innovation of China

基　　金：上饶市科技计划项目(2023CZDX159)。

摘　　要：目的:探究替罗非班治疗不同部位进展性脑梗死(PIS)的临床效果。方法:选取97例2023年1月—2024年1月上饶市人民医院收治的PIS患者,根据梗死部位不同将其分为前循环组(n=47)、后循环组(n=50)。两组均给予基础治疗+替罗非班治疗。比较两组血小板参数、神经功能缺损程度、临床疗效及不良事件发生情况。结果:治疗1周后,两组血小板体积分布宽度(PDW)、平均血小板体积(MPV)均减小,血小板计数(PLT)均上升,后循环组PDW和MPV均小于前循环组,PLT高于前循环组,差异均有统计学意义(P<0.05)。入院时,两组美国国立卫生研究院卒中量表(NIHSS)评分比较,差异无统计学意义(P>0.05);治疗2 d、1周后,后循环组NIHSS评分均低于前循环组,差异均有统计学意义(P<0.05)。后循环组总有效率(86.00%)高于前循环组(68.09%),差异有统计学意义(P<0.05)。后循环组不良事件总发生率(8.00%)与前循环组(14.89%)比较,差异无统计学意义(P>0.05)。结论:替罗非班治疗PIS效果确切,可有效改善患者血小板参数和神经功能,其对后循环梗死患者的病情改善更显著,且安全性较高。Objective:To explore the clinical effect of Tirofiban in the treatment of different sites of progressive ischemic stroke(PIS).Method:A total of 90 patients with PIS admitted to Shangrao People's Hospital from January 2023 to January 2024 were selected and divided into anterior circulation group(n=47)and posterior circulation group(n=50)according to different infarct sites.Both groups were given basic treatment+Tirofiban treatment.Platelet parameters,neurological deficit degree,clinical efficacy and adverse events were compared between the two groups.Result:After 1 week of treatment,platelet distribution width(PDW)and mean platelet volume(MPV)decreased in both groups,and platelet count(PLT)increased,PDW and MPV in posterior circulation group were smaller than those in anterior circulation group,and PLT was higher than that in anterior circulation group,the differences were statistically significant(P<0.05).At admission,there was no significant difference in national institutes of health stroke scale(NIHSS)scores between the two groups(P>0.05).After 2 days and 1 week of treatment,the NIHSS scores of posterior circulation group were lower than those of anterior circulation group,the differences were statistically significant(P<0.05).The total effective rate of posterior circulation group(86.00%)was higher than that in anterior circulation group(68.09%),the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse events between posterior circulation group(8.00%)and anterior circulation group(14.89%)(P>0.05).Conclusion:Tirofiban is effective in the treatment of PIS,and can effectively improve the platelet parameters and nerve function of patients,and it can improve the condition of patients with posterior circulation infarction more significantly,and has higher safety.

关 键 词：前循环梗死 后循环梗死 进展性脑梗死 替罗非班 血小板参数 神经功能缺损 

分 类 号：R743.33[医药卫生—神经病学与精神病学]